MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.
See also LY-2183240 URB-597 PF-3845 BIA 10-2474
References
External links "MK 4409". Adis Insight. Springer Nature Switzerland AG.


